乳腺癌放疗后，心脏平均受照剂量每增加1 Gray，主要冠状动脉事件的发生率就上升7.4%，呈线性关系且没有阈值（Darby 2013）。
原始表述
ارتفاع متناسب لأمراض القلب الإقفارية بـ7.4% لكل غراي من إشعاع الصدر
非原话——为转述. 译文由本项目提供；以阿拉伯语原文为准。
译文
乳腺癌放疗后，心脏平均受照剂量每增加1 Gray，主要冠状动脉事件的发生率就上升7.4%，呈线性关系且没有阈值（Darby 2013）。
出处
- 来源状态
- 档案网站编辑
- 归属
- Archive editors (rule page summary/narrative)
- 出处
- https://eltayebat.com/rule/chemo-radiation/
- 归属的不确定性
- Written by archive operators; not attributed to Elawady.
- 所声称的机制
Radiation damage to coronary arteries
- 所声称的健康影响
Ischaemic heart disease
- 涉及人群
Women irradiated for breast cancer
- Elawady 设定的地域限制
none found
科学评估
基本正确 – 核心内容正确，但有局限或细微不准确之处。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么？
7.4% per Gray increase in ischaemic heart disease after breast irradiation; 'the heaviest blow'.
2. 哪些内容可证实是正确的？
Darby et al. found +7.4% per Gy mean heart dose (95% CI 2.9-14.5), starting within 5 years and lasting into the third decade (A-CHM-04).
3. 哪些内容是错误或夸大的？
The unit is mean dose to the heart, not 'per Gray of chest irradiation'. A relative 7.4%/Gy on a low baseline risk translates into small absolute risks with modern doses: estimated radiation-related cardiac mortality about 0.3% in non-smokers and about 1% in smokers (I-CHM-06). The same radiotherapy halves recurrence and reduces breast-cancer death (I-CHM-02).
4. 哪些内容仍不明确？
Risk at very low modern heart doses with heart-sparing techniques.
5. 哪些研究支持该说法？
6. 哪些研究与该说法相矛盾？
7. 对德国和欧洲而言情况如何？
European centres use heart-sparing techniques; risk communication in absolute terms recommended.
8. 关于埃及的已知情况是什么？
Not studied; doses depend on equipment and techniques available.
9. 合理的实际结论是什么？
尽量降低心脏受照剂量，并控制心脏危险因素（尤其是吸烟）；有指征的放疗所带来的获益通常超过其心脏风险。
评估详情
- 证据确定性的依据
The figure is reported correctly from a well-conducted population-based case-control study; consistent with randomised-trial meta-analysis (I-CHM-06). Downgraded because the archive presents a relative per-Gy increase without absolute risk, and the Arabic summary refers to 'chest irradiation' instead of mean heart dose.
- 来源质量
Correctly cited landmark study.
- 地区可推广性
High.
- 个体例外情况
Women with cardiac risk factors have larger absolute increases.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
有充分科学证据支持 – 该说法与一致的高质量证据相符。
研究问题: After breast-cancer radiotherapy, does the rate of major coronary events increase linearly by about 7.4% per Gy of mean heart dose without a threshold, and what does this mean in absolute terms?
研究问题详解 (PECO)
- 人群
- Women treated with radiotherapy for breast cancer
- 干预或暴露
- Mean heart dose (Gy)
- 对照
- Lower dose
- 地域范围
- universal biology
- 结局指标
- Major coronary events
- Cardiac mortality
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Radiation dose to the heart during breast-cancer radiotherapy raises later heart-attack risk
Population-based case-control study: coronary events rose linearly with mean heart dose.
- 实际结果
- 7.4% per Gy (2.9-14.5), no threshold, from within 5 years into the third decade
- 方法学质量
- high (large population-based design, individual dosimetry)
- 相关性
- direct
- 局限
- Relative measure; older techniques
Heart dose and heart attacks after breast radiotherapy: a check of Darby
van den Bogaard VA et al.. J Clin Oncol 2017 · PMID 28095159 · DOI 10.1200/JCO.2016.69.8480 队列研究已核查摘要新增Independent Dutch cohort with 3D CT dosimetry replicated the dose-response.
- 实际结果
- 16.5% per Gy (0.6-35.0); median heart dose 2.37 Gy
- 方法学质量
- moderate (cohort, few events)
- 相关性
- direct
- 局限
- Imprecise slope
哪些证据不支持该说法？
With modern techniques, radiotherapy's heart and lung risks are small for non-smokers
Modern radiotherapy doses translate into small absolute cardiac mortality risks, larger in smokers.
- 实际结果
- Cardiac mortality about 0.3% (non-smokers) and about 1% (long-term smokers)
- 方法学质量
- high (meta-analysis plus dosimetry)
- 相关性
- direct (limits the practical meaning)
- 局限
- Model-based absolute estimates
Radiotherapy after breast-conserving surgery halves recurrence
Radiotherapy after breast-conserving surgery reduces recurrence and breast cancer death.
- 实际结果
- 15-year breast cancer death 21.4% vs 25.2%; all-cause -3.0 points
- 方法学质量
- high (IPD meta-analysis)
- 相关性
- indirect (benefit side)
- 局限
- Older trials
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
The 7.4%/Gy figure is reported correctly and has been replicated; it is a relative increase.
为什么有些研究权重更大
Darby is the pivotal study; van den Bogaard replicates with modern dosimetry; Taylor provides absolute risk.
因果关系是否已确立？ 是，已确立 Dose-response, replication, biological plausibility.
仍存在的不确定性
Shape of the curve at very low doses; substructure doses may be better predictors.
合理的结论
Correct as a relative dose-response. With modern mean heart doses of about 1-3 Gy, the relative increase is roughly 7-20%, corresponding to small absolute risks (about 0.3% radiation-related cardiac death in non-smokers).
这是否取决于国家？
- 一般生物学效应
- Universal radiobiology; depends on the technique used (breath-hold, 3D planning).
- 饮食习惯
- Not relevant.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant.
- 本国生产条件
- Not relevant.
- 法律规则
- Not relevant.
- 实际监测数据
- No monitoring data relevant.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Relative vs absolute; CI shape – 7.4%/Gy is an excess relative risk on a linear scale; asymmetric CI (2.9-14.5) is expected for a profile-likelihood interval; not log-symmetric by design 已重新计算
- Translate slope at typical dose – At 2.37 Gy: +17.5% (Darby slope) to +39% (van den Bogaard slope, imprecise) 已重新计算
- NNH vs NNT – Radiation-related cardiac death NNH about 333 (non-smokers) vs NNT about 26 to prevent one breast cancer death (I-CHM-02) 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Major coronary events per Gy mean heart dose
- 起始等级
- 低（观察性研究）
- 升级理由
- dose-response
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ESC: 2022 ESC Guidelines on cardio-oncology (with EHA, ESTRO, IC-OS) (2022) · 原始文献
The ESC guideline page states that this first ESC cardio-oncology guideline covers definitions, diagnosis, treatment and prevention of cancer-therapy-related cardiovascular toxicity before, during and after cancer treatment, and that evidence is limited so expert consensus is used where needed. The page lists the Egyptian Society of Cardiology among endorsing national societies. Detailed recommendations (full text, Eur Heart J 2022; PMID 36017568) could not be fetched (HTTP 403) and were not used.
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | (TITLE:"acute coronary events" OR TITLE:"ischemic heart disease" OR TITLE:"coronary") AND TITLE:"breast cancer" AND (TITLE:"radiotherapy" OR TITLE:"radiation") AND (TITLE:"dose" OR TITLE:"validation") AND PUB_YEAR:[2014 TO 2026] | 双向 | 25 | |
| Europe PMC | 2026年10月26日 | TITLE:"Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy" | 支持性证据 | 1 |
待解决的问题
Absolute risks with current cardiac-sparing techniques in Egypt (technique availability not reviewed).
核查深度如何？
4 项相关研究：1 项核查了全文（其中 1 项进行了结构化偏倚风险评估），3 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
通俗解释
乳腺癌放疗时，射线可能照到心脏。心脏每多受一个单位的辐射剂量，日后发生心脏病发作的风险就增加几个百分点。采用现代技术时，心脏受照剂量很小，因此对不吸烟者来说，额外风险约为每1,000人中3人。同样的放疗能使乳腺癌复发的机会减半。不吸烟还能进一步降低心脏风险。
与该说法相关的研究
支持该说法的研究 (2)
-
Radiation dose to the heart during breast-cancer radiotherapy raises later heart-attack risk
Darby SC et al.. N Engl J Med 2013 · PMID 23484825 · DOI 10.1056/NEJMoa1209825病例对照研究被 Tayebat 档案网站引用已核查摘要★ 关键研究Each extra Gray of average heart dose increased the rate of major coronary events by about 7%.
Source of the 7.4%/Gy figure
该研究是否支持这一具体说法？ 是 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Measure heart risk by radiation dose.
- 研究是如何开展的？
Case-control with dose reconstruction.
- 研究了多少人、动物或样本？
2,168 women.
- 实际发现了什么？
+7.4% per Gy, linear.
- 观察到的效应有多大？
ERR 7.4%/Gy (2.9-14.5).
- 研究结果对日常生活意味着什么？
Keep heart dose as low as possible; control cardiac risk factors.
- 该研究有哪些局限？
Historical doses; relative measure.
- 它对 Elawady 的具体说法说明了什么？
Confirms the archive number.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
That radiotherapy does net harm.
-
Heart dose and heart attacks after breast radiotherapy: a check of Darby
van den Bogaard VA et al.. J Clin Oncol 2017 · PMID 28095159 · DOI 10.1200/JCO.2016.69.8480队列研究独立交叉核查已核查摘要Risk of acute heart events rose by about 16.5% per Gy of heart dose; the typical heart dose was low (2.4 Gy).
Independent replication of a linear dose-response for coronary events after breast radiotherapy.
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Check the Darby dose-response
- 研究是如何开展的？
Cohort with 3D dose data
- 研究了多少人、动物或样本？
910 Dutch women
- 实际发现了什么？
Dose-response confirmed
- 观察到的效应有多大？
16.5%/Gy (0.6-35.0)
- 研究结果对日常生活意味着什么？
Lower heart dose means lower risk; modern doses are low
- 该研究有哪些局限？
Few events
- 它对 Elawady 的具体说法说明了什么？
Supports the 7.4%/Gy claim as relative risk
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Does not give absolute lifetime risk
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (2)
-
With modern techniques, radiotherapy's heart and lung risks are small for non-smokers
Taylor C et al.. J Clin Oncol 2017 · PMID 28319436 · DOI 10.1200/JCO.2016.72.0722Meta分析独立交叉核查已核查摘要★ 关键研究About 0.3% risk of radiation-related heart death or lung cancer in non-smokers, higher in smokers.
Absolute risk small with modern doses
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Estimate absolute RT risks.
- 研究是如何开展的？
Dose review + IPD meta-analysis.
- 研究了多少人、动物或样本？
40,781 women.
- 实际发现了什么？
Small absolute risks; smoking key.
- 观察到的效应有多大？
Cardiac mortality RR 1.30.
- 研究结果对日常生活意味着什么？
Stop smoking before/after radiotherapy.
- 该研究有哪些局限？
Smoking modelled.
- 它对 Elawady 的具体说法说明了什么？
Puts Darby in perspective.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Individual dose-specific risk.
-
Radiotherapy after breast-conserving surgery halves recurrence
EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2Meta分析独立交叉核查全文，含结构化偏倚风险评估★ 关键研究Recurrence within 10 years fell from 35% to 19%, and breast-cancer deaths within 15 years from 25% to 21%.
Benefit context for the heart risk
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Measure radiotherapy benefit.
- 研究是如何开展的？
IPD meta-analysis.
- 研究了多少人、动物或样本？
10,801 women.
- 实际发现了什么？
Recurrence halved; breast-cancer deaths about one-sixth lower; deaths from any cause at 15 years 3.0 percentage points lower.
- 观察到的效应有多大？
-15.7% recurrence; -3.8% death.
- 研究结果对日常生活意味着什么？
Radiotherapy markedly lowers the chance the cancer returns.
- 该研究有哪些局限？
Older techniques; risk groups derived from the same data; in low-risk node-negative women the gain in survival was small and uncertain.
- 它对 Elawady 的具体说法说明了什么？
Benefit side.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Individual benefit size without risk factors.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (0)
该组中没有研究。
地区背景
德国 / 欧盟
European centres use heart-sparing techniques; risk communication in absolute terms recommended.
埃及
Not studied; doses depend on equipment and techniques available.
在我的国家适用什么？
一般科学评估
基本正确 “每Gy增加7.4%”这一数字是正确的，但属于相对值；在现代剂量下，绝对风险很小，通常被获益所抵消。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Risk of ischemic heart disease in women after radiotherapy for breast cancer.. Darby SC et al.. N Engl J Med 2013 · PMID 23484825 · DOI 10.1056/NEJMoa1209825
- Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures.. van den Bogaard VA et al.. J Clin Oncol 2017 · PMID 28095159 · DOI 10.1200/JCO.2016.69.8480
- Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.. Taylor C et al.. J Clin Oncol 2017 · PMID 28319436 · DOI 10.1200/JCO.2016.72.0722
- Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.. EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2